ADDI-2018 Program

ADDI-2018: HONG KONG

Inaugural Asian Conference on Drug-Drug Interactions

Pioneer Lectures:  Tools and Experimental Approaches for Assessment of Drug-drug Interactions; Regulatory Requirements for Drug-drug Interaction Evaluation; Transporter-mediated Drug-drug Interactions; Drug Metabolizing Enzyme-mediated Drug-drug Interactions; Atypical Drug-drug Interactions; Novel Technologies for the Evaluation of Drug-drug Interactions; Herb-drug Interactions

December 3-6, 2018

 

Venue: Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK

REGISTRATION DISCOUNT UNTIL November 3, 2018

ADDI-2018 is an event providing a comprehensive update on the status of the science of drug-drug interactions and its relevance to drug development. The conference will include a review on the current status of DDI potential of biologics, industrial perspectives and other relevant topics.

Organizing Chairs:

Albert P. Li, APSciences/In Vitro ADMET Laboratories, Inc.

Yuichi Sugiyama, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN

Joan Zuo, The Chinese University, Hong Kong

Genfu Chen, WuXi AppTec

Chuang Lu, Sanofi

Lilly Xu, ChemPartner

 

Monday, December 3, 2018:

7:00 AM – 8:00 AM – REGISTRATION

 

8:00 AM – 8:15 AM

Welcome Remarks: Albert P. Li, APSciences/IVAL

 

Session 1: Pioneer Lectures:  Tools and Experimental Approaches for Assessment of Drug-drug Interactions (Chair:  Joan Zuo, The Chinese University, Hong Kong)

 

8:15 AM – 8:45 AM

Mechanisms and Clinical Significance of Hepatic Drug-drug Interactions Involving Efflux Drug Transporters (Kim Brouwer, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA)

 

8:45 AM – 9:15 AM

Extrapolation of In Vitro Drug-drug Interaction Data to In Vivo Clinical Findings (Yuichi Sugiyama, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN; Yokohama, Japan)

 

9:15 AM – 9:45 AM

In Vitro Human-based Experimental Systems for the Evaluation of Drug-drug Interactions; Hepatocytes, Enterocytes and beyond (Albert P. Li, IVAL; Columbia, MD, USA)

 

9:45 AM – 10:15 AM – BREAK

 

10:15 AM – 10:45 AM – PANEL DISCUSSION: SESSION 1

 

Session 2: Regulatory Requirements for Drug-drug Interaction Evaluation (Chair:  Genfu Chen, WuXi AppTec)

 

10:45 AM – 11:15 AM

The Pre-clinical DDI Guidance: Comparison Between USA FDA, EU, Japan and China, (Zhuohan Hu, Research Institute of Liver Disease (Shanghai) Co Ltd. Shanghai, China)

 

11:15 AM – 11:45 AM

DDI guidance: The Clinical Focus (Sylvia Zhao, China Novartis Institutes of Biomedical Research, Shanghai, China)

 

11:45 AM – 1:45 PM – LUNCH

 

1:45 PM – 2:15 PM

Mechanistic Analysis of the Risk of Pharmacokinetic Drug-drug Interactions with Drugs Recently Approved by the US Food and Drug Administration (Jingjing Yu, University of Washington; Seattle, WA, USA)

 

2:15 PM – 2:45 PM

Clinical Trial on DDI Risk Assessment – Case Studies, (Min Huang, Sun Yat-sen University, Guangzhou, China)

 

2:45 PM – 3:15 PM – BREAK

 

3:15 PM – 3:45 PM – PANEL DISCUSSION-SESSION 2

 

Reception/Vendor presentations: Time TBD

Social event:  Reception; Performance by Hong Kong Traditional Dancers

 

Tuesday, December 4, 2018:

 

7:00 AM – 8:00 AM – REGISTRATION

 

Session 3: Transporter-mediated Drug-drug Interactions (Chair:  Yuichi Sugiyama, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, RIKEN)

 

8:00 AM – 8:30 AM

The In Vitro Assays for Evaluating BSEP Inhibition Potencies of Drugs (Sumito Ito, Genomembrane, Kanagawa, Japan)

 

8:30 AM – 9:00 AM

Predicting Complex DDIs Related to CYP Induction and OATP Inhibition by PBPK Model of Rifampicin with its own Hepatic Uptake and Auto-induction, (Ryuta Asaumi, Ono Pharmaceutical, Ibaraki, Japan)

 

9:00 AM – 9:30 AM

Application of PBPK Modeling to Renal OCT2 and MATEs mediated DDIs: Predicting Changes in Renal Clearance and Blood AUC Caused by the Transporter Inhibitors. (Kotaro Nishiyama, Nippon Boehringer Ingelheim, Kobe, Japan)

 

9:30 AM – 10:00 AM – BREAK

 

10:00 AM – 10:30 AM

Quantitative Analysis of Complex Drug-drug Interactions using PBPK Models with In Vitro Inhibition Data: Repaglinide and Cerivastatin (Soo-Jin Kim, CJ HealthCare, Seoul, Republic of Korea)

 

10:30 AM – 11:00 AM

Usefulness of a Model-based Approach for Estimating In Vitro P-glycoprotein Inhibition Potency in a Transcellular Transport Assay, (Naoki Ishiguro, Nippon Boehringer Ingelheim, Kobe, Japan)

 

11:00 AM – 11:30 AM

Case Study on Renal Transporter mediated DDI: Weak Interactions between Metformin and Fampridine, an OCT2 but not MATE Substrate (Guangqing Xiao, Takeda Pharmaceuticals International Co., Cambridge, MA, USA)

 

11:30 AM – 12:00 PM

Hepatocellular Disposition Profiling of Rosuvastatin and Pitavastatin in Sandwich-Cultured Human Hepatocytes: BCRP inhibitor, Ko143, Decreased not only Biliary Excretion but also Basolateral Efflux of Rosuvastatin (Katsuhiro Kanda, Hitachi High-Technologies Corporation, Ibaraki, Japan)

 

12:00 PM – 12:30 PM – PANEL DISCUSSION-SESSION 3

 

Social event:  Tour of Chinese University of Hong Kong

Free afternoon

Wednesday, December 5, 2018

 

7:00 AM – 8:00 AM – REGISTRATION

 

Session 4: Drug Metabolizing Enzyme-mediated Drug-drug Interactions (Chair:  Chuang Lu, Sanofi)

 

8:00 AM – 8:30 AM

PBPK modeling to describe intestinal vs. liver handling and DDI (K. Sandy Pang, University of Toronto, Toronto, Canada)

 

8:30 AM – 9:00 AM

Use of Cluster Newton Method to Obtain Reliable In Vivo Ki Values by Analyzing the Change in Pharmacokinetics of both Parent and Metabolites of Victim Compound (Kazuya Maeda, The University of Tokyo, Tokyo, Japan)

 

9:00 AM – 9:30 AM

Assessment of CYP1A2 Inductive Potential of Edaravone, a New Drug Approved for ALS, and Necessity Judgment of the Clinical DDI Study (Norihiko Iwazaki, Mitsubishi-Tanabe Pharma Corporation, Saitama, Japan)

 

9:30 AM – 10:00 AM – BREAK

 

10:00 AM – 10:30 AM

CYP3A5 Allosteric Activation and its Mechanism Research (Xiaomei Zhuang, Beijing Institute of Pharmacology and Toxicology, Beijing, China)

 

10:30 AM – 11:00 AM

Prediction of Time-dependent DDI with CYP3A in the Liver and Intestine Based on the PBPK Modeling and Comparison with Data from Clinical DDI Study (Toru Takenaka, Taiho Pharmaceutical Co., LTD., Tsukuba, Japan)

 

11:00 AM – 11:30 AM – PANEL DISSCUSSION SESSION 4

 

11:30 AM – 1:30 PM – LUNCH BREAK

 

Session 5: Atypical Drug-drug Interactions (Chair:  Lilly Xu, Chem Partner)

 

1:30 PM – 2:00 PM

Target-mediated Drug Disposition in Small Molecule Drugs: Its Role in Atypical Pharmacokinetic Non-linearity and DDI (Wooin Lee, Seoul National University, Seoul, Korea)

 

2:00 PM – 2:30 PM

Physiologically-based Pharmacokinetic Analysis of Nonlinear Pharmacokinetics of Paclitaxel and Drug Interactions with other Drugs (Nora Lee, Daewoong Pharmaceutical, Seoul, Republic of Korea)

 

2:30 PM – 3:00 PM

Recent Advances in Reaction Phenotyping to Access Victim Drug-Drug Interaction (Li Di, Pfizer Inc., Groton, CT, USA)

 

3:00 PM – 3:30 PM – BREAK

 

3:30 PM – 4:00 PM

Application of In Vitro “Dissolution/permeation (D/P) System” to Predict Absorption-based Drug-drug Interaction (Shoko Takeyama, Daiichi Sankyo RD Novare Co., Ltd; Tokyo, Japan)

 

4:00 PM – 4:30 PM

HLA, CYP, and DDI; the SCAR Determinant and Contributing Factors (Chonlaphat Sukasem, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand)

 

4:30 PM – 5:00 PM

Unraveling Gut Microbiota-herb Interactions Employing 16S rRNA Microbial Sequencing and Metabolomics. (Ru Yan, University of Macau, Taipa, Macao, China)

 

5:00 PM – 5:30 PM – PANEL DISCUSSION SESSION 5

  

Social event:  Symposium banquet

 

Thursday. December 6, 2018

 

7:00 AM – 8:00 AM – REGISTRATION

 

Session 6:  Novel Technologies for the Evaluation of Drug-drug Interactions (Chair:  Albert P. Li, IVAL)

 

8:00 AM – 8:30 AM 

Novel In Vitro Methods for Clinical DDI Prediction (Chuang Lu, Sanofi, Cambridge, MA, USA)

 

8:30 AM – 9:00 AM

Alterations in Bile Acid Transport in Human Hepatocytes as a Predictive Tool to Evaluate DILI Potential in Drug Development (Kenneth Brouwer, BioIVT, Durham, NC, USA)

 

9:00 AM – 9:30 AM

Case Study for Improvements of CYP DDI Victim Risk GAP between Perspective and Retrospective Prediction Using New ADME Tools, Chimeric Mice (Daisuke Tenmizu, Astellas Pharma Inc., Tsukuba, Japan)

 

9:30 AM – 10:00 AM – BREAK

 

10:00 AM – 10:30 AM

Drug-Vitamin Transporter Interaction: Are We Ready for a Thiamine Transporter (THTR2) Decision Tree?  (Yan Zhang, Incyte Corporation, Wilmington, DE, USA)

 

10:30 AM – 11:00 AM

Preclinical Evaluation of Drug-Drug Interaction Potential in Drug Discovery:  Challenging the Status Quo (Simon G. Wong, Genentech, South San Francisco, California, USA)

 

11:00AM – 11:30 AM – PANEL DISCUSSION SESSION 6

 

11:30 AM – 1:30 PM – LUNCH BREAK

 

Session 7: Herb-drug Interactions (Chair:  Joan Zuo, CUHK)

 

1:30 PM – 2:00 PM

East meets West: Overview of Herb-drug Interaction Research in Hong Kong (Joan Zuo, CUHK, Hong Kong, China)

 

2:00 PM – 2:30 PM

A Pragmatic Approach to Review Herb-drug Interactions for Implementation of Integrative Medicine (Timothy Yung, Hospital Authority of Hong Kong, Hong Kong, China)

 

2:30 PM – 3:00 PM

Beneficial Herb-drug Interaction in the Combinational Use of Herbal Polyoxypregnanes with Paclitaxel (Ge Lin, The Chinese University of Hong Kong, Hong Kong, China) 

 

3:00 PM – 3:30 PM – BREAK

 

3:30 PM – 4:00 PM

Herbal Medication and Liver Diseases (Huichang Bi, Sun Yat-sen University, Guangzhou, China)

 

4:00 PM – 4:30 PM

Herbal Medication Mediated CYP or Transporter based DDI and PBPK Modeling for Risk Assessment (Chuan Li, Chinese Academy of Science, Beijing, China) 

 

4:30 PM – 5:00 PM

Herb-drug Interactions – Do they Matter in the Clinic?  (Brian Tomlinson, The Chinese University of Hong Kong, Shatin, Hong Kong, China)

 

5:00 PM – 5:30 PM – PANEL DISCUSSION SESSION 7

 

5:30 PM – 6:00 PM – Closing Remarks (Albert P. Li, IVAL)